PBAC's latest decision on Emtricitabine + tenofovir alafenamide: Recommended with restriction (2016). Considered for Treatment of human immunodeficiency virus (HIV) infection in treatment-naïve and treatment-experienced patients, administered in combination with other antiretroviral agents.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2016
Submissions
1
2016 → 2016
Eligible population
Treatment-naïve patients and treatment-experienced patients with HIV infection receiving combination antiretroviral therapy
Therapy area
Infectious disease
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Truvada®
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis conducted; no incremental ICER calculated